Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for women with mysterious chest pain: tailored treatment on the horizon

NCT ID NCT07593157

Disease control Sponsor: Hospital de Clínicas Dr. Manuel Quintela Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for women with chest pain who don't have blocked arteries. Doctors will use special tests to find the exact cause of the pain, then give each woman a personalized treatment plan. The goal is to see if this tailored approach improves symptoms and quality of life over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
individualized pharmacological treatment (antianginal, vasodilator, or endothelial-targeted drugs)
What this could lead to
If successful, this could lead to a more effective, personalized treatment strategy for women with chest pain and non-obstructive coronary arteries, improving their symptoms and daily life.
What could go wrong
This is a small, early-stage study at a single center, so results may not apply to all patients. The invasive procedures carry some risk, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 35 to 75 years. * Symptoms compatible with stable angina or suspected myocardial ischemia. * Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%. * Ability to undergo invasive coronary assessment and clinical follow-up. * Written informed consent. Exclusion Criteria: * Significant structural heart disease. * Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \<40%. * Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity. * Active oncological disease or life expectancy less than 12 months. * Inability to complete the diagnostic or therapeutic study protocol. * Participation in another clinical study that could interfere with the present protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anoca - angina with non-obstructive coronary arteries are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder Prinzmetal angina

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anoca - angina with non-obstructive coronary arteries Coronary microvascular dysfunction (CMD) Vasospastic angina

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital de Clínicas Dr. Manuel Quintela

    Montevideo, Montevideo Department, 11600, Uruguay

More trials for these conditions

Other studies related to the condition(s) this trial covers.